<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="/rss.css" type="text/css"?>
<rdf:RDF xmlns="http://purl.org/rss/1.0/"
    xmlns:cc="http://web.resource.org/cc/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:extra="http://www.w3.org/1999/xhtml"
    xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
    <channel rdf:about="http://www.immunityageing.com/feeds/mostaccessed/journal?quantity=&amp;format=rss&amp;version=">
        <title>Immunity &amp; Ageing - Most accessed articles</title>
        <link>http://www.immunityageing.com</link>
        <description>The most accessed research articles published by Immunity &amp; Ageing</description>
        <dc:date>2010-02-02T00:00:00Z</dc:date>
        <items>
            <rdf:Seq>
                                <rdf:li rdf:resource="http://www.immunityageing.com/content/7/1/1" />
                                <rdf:li rdf:resource="http://www.immunityageing.com/content/2/1/9" />
                                <rdf:li rdf:resource="http://www.immunityageing.com/content/6/1/12" />
                                <rdf:li rdf:resource="http://www.immunityageing.com/content/4/1/1" />
                                <rdf:li rdf:resource="http://www.immunityageing.com/content/6/1/13" />
                                <rdf:li rdf:resource="http://www.immunityageing.com/content/6/1/4" />
                                <rdf:li rdf:resource="http://www.immunityageing.com/content/2/1/17" />
                                <rdf:li rdf:resource="http://www.immunityageing.com/content/7/1/3" />
                                <rdf:li rdf:resource="http://www.immunityageing.com/content/6/1/9" />
                                <rdf:li rdf:resource="http://www.immunityageing.com/content/7/1/2" />
                            </rdf:Seq>
        </items>
        <extra:info rdf:parseType="Literal">
            <html:div style="font:14px Verdana, Geneva, Arial, Helvetica, sans-serif" xmlns:html="http://www.w3.org/1999/xhtml">
                <html:span style="font-weight:bold">
                    This is an RSS newsfeed from BioMed Central
                </html:span>
                <html:br />
                <html:span style="font-size: 12px;">
                    It is intended to be used with an RSS reader. For more information about RSS newsfeeds from BioMed Central, visit
                    <html:br />
                    <html:a href="http://www.biomedcentral.com/info/about/rss/" style="color:#3333CC; font-size:12px;">
                        http://www.biomedcentral.com/info/about/rss/
                    </html:a>
                    <html:br />
                </html:span>
            </html:div>
        </extra:info>
        <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </channel>
        <item rdf:about="http://www.immunityageing.com/content/7/1/1">
        <title>Curcumin, inflammation, ageing and age-related diseases</title>
        <description>A Symposium regarding the Pathophysiology of Successful and Unsuccessful Ageing was held in Palermo, Italy between April 7 and 8th 2009. Here the lecture by Sikora with some input from the chairpersons Scapagnini and Barbagallo is summarized. Ageing is manifested by the decreasing health status and increasing probability to acquire age-related disease such as cancer, Alzheimer&apos;s disease, atherosclerosis, metabolic disorders and others. They are likely caused by low grade inflammation driven by oxygen stress and manifested by the increased level of pro-inflammatory cytokines such as IL-1, IL-6 and TNF-&#945;, encoded by genes activated by the transcription factor NF-&#954;B. It is believed that ageing is plastic and can be slowed down by caloric restriction as well as by some nutraceuticals. Accordingly, slowing down ageing and postponing the onset of age-related diseases might be achieved by blocking the NF-&#954;B-dependent inflammation. In this review we consider the possibility of the spice curcumin, a powerful antioxidant and anti-inflammatory agent possibly capable of improving the health status of the elderly.</description>
        <link>http://www.immunityageing.com/content/7/1/1</link>
                <dc:creator>Ewa Sikora</dc:creator>
                <dc:creator>Giovanni Scapagnini</dc:creator>
                <dc:creator>Mario Barbagallo</dc:creator>
                <dc:source>Immunity &amp; Ageing 2010, 7:1</dc:source>
        <dc:date>2010-01-17T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1742-4933-7-1</dc:identifier>
        <prism:publicationName>Immunity &amp; Ageing</prism:publicationName>
        <prism:issn>1742-4933</prism:issn>
        <prism:volume>7</prism:volume>
        <prism:startingPage>1</prism:startingPage>
        <prism:publicationDate>2010-01-17T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.immunityageing.com/content/2/1/9">
        <title>Total and specific serum IgE decreases with age in patients with allergic rhinitis, asthma and insect allergy but not in patients with atopic dermatitis</title>
        <description>Concerning allergic diseases, the incidence of allergic symptoms, as well as their severity, seems to decrease with age. The decline of onset of allergic symptoms observed in ageing might result from a decrease of serum total and specific IgE. Atopic disorders are complex diseases that involve interactions among several physiological systems, e.g. skin, lung, mucosae, and the immune system. It was the aim of this study to compare the effects of age on total and specific IgE in patients with atopic dermatitis (AD), allergic rhinitis or asthma, and insect allergy, respectively.The study population consisted of 559 individuals (male: 229 and female: 330). Total and allergen specific IgE was measured in every individual. From the whole study population, 113 patients suffered from atopic dermatitis (AD), 132 had allergic rhinitis or asthma, and 314 were tested because of insect allergy. Total and specific serum IgE was significantly decreased as a function of age in patients with allergic rhinitis and asthma and with insect allergy. In contrast, no significant decrease of total and specific serum IgE in old individuals with AD was observed. Additionally, in the group of patients with a total IgE &lt; 300 kU/l a reduction of total serum IgE was significantly correlated with age. In contrast, patients with IgE levels &gt; 300 kU/l showed no correlation with age.Immunosenescence does not affect increased IgE levels in atopic patients with AD and/or high serum IgE levels indicating that in these subgroups of patients the atopic propensity remains into advanced age. One may hypothesize that either onset of allergic sensitization during life or the kind of atopic disease influences the correlation between age and IgE synthesis.</description>
        <link>http://www.immunityageing.com/content/2/1/9</link>
                <dc:creator>Anja Mediaty</dc:creator>
                <dc:creator>Karsten Neuber</dc:creator>
                <dc:source>Immunity &amp; Ageing 2005, 2:9</dc:source>
        <dc:date>2005-05-31T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1742-4933-2-9</dc:identifier>
        <prism:publicationName>Immunity &amp; Ageing</prism:publicationName>
        <prism:issn>1742-4933</prism:issn>
        <prism:volume>2</prism:volume>
        <prism:startingPage>9</prism:startingPage>
        <prism:publicationDate>2005-05-31T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.immunityageing.com/content/6/1/12">
        <title>Pathophysiology of age-related diseases</title>
        <description>A Symposium regarding the Pathophysiology of Successful and Unsuccessful Ageing was held in Palermo, Italy on 7-8 April 2009. Three lectures from that Symposium by G. Campisi, L. Ginaldi and F. Licastro are here summarized. Ageing is a complex process which negatively impacts on the development of various bodily systems and its ability to function. A long life in a healthy, vigorous, youthful body has always been one of humanity&apos;s greatest dreams. Thus, a better understanding of the pathophysiology of age-related diseases is urgently required to improve our understanding of maintaining good health in the elderly and to program possible therapeutic intervention.</description>
        <link>http://www.immunityageing.com/content/6/1/12</link>
                <dc:creator>Giuseppina Campisi</dc:creator>
                <dc:creator>Martina Chiappelli</dc:creator>
                <dc:creator>Massimo De Martinis</dc:creator>
                <dc:creator>Vito Franco</dc:creator>
                <dc:creator>Lia Ginaldi</dc:creator>
                <dc:creator>Rosario Guiglia</dc:creator>
                <dc:creator>Federico Licastro</dc:creator>
                <dc:creator>Domenico Lio</dc:creator>
                <dc:source>Immunity &amp; Ageing 2009, 6:12</dc:source>
        <dc:date>2009-09-08T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1742-4933-6-12</dc:identifier>
        <prism:publicationName>Immunity &amp; Ageing</prism:publicationName>
        <prism:issn>1742-4933</prism:issn>
        <prism:volume>6</prism:volume>
        <prism:startingPage>12</prism:startingPage>
        <prism:publicationDate>2009-09-08T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.immunityageing.com/content/4/1/1">
        <title>The Interleukin-6 inflammation pathway from cholesterol to aging - Role of statins, bisphosphonates and plant polyphenols in aging and age-related diseases </title>
        <description>We describe the inflammation pathway from Cholesterol to Aging. Interleukin 6 mediated inflammation is implicated in age-related disorders including Atherosclerosis, Peripheral Vascular Disease, Coronary Artery Disease, Osteoporosis, Type 2 Diabetes, Dementia and Alzheimer&apos;s disease and some forms of Arthritis and Cancer. Statins and Bisphosphonates inhibit Interleukin 6 mediated inflammation indirectly through regulation of endogenous cholesterol synthesis and isoprenoid depletion. Polyphenolic compounds found in plants, fruits and vegetables inhibit Interleukin 6 mediated inflammation by direct inhibition of the signal transduction pathway. Therapeutic targets for the control of all the above diseases should include inhibition of Interleukin-6 mediated inflammation.</description>
        <link>http://www.immunityageing.com/content/4/1/1</link>
                <dc:creator>Sota Omoigui</dc:creator>
                <dc:source>Immunity &amp; Ageing 2007, 4:1</dc:source>
        <dc:date>2007-03-20T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1742-4933-4-1</dc:identifier>
        <prism:publicationName>Immunity &amp; Ageing</prism:publicationName>
        <prism:issn>1742-4933</prism:issn>
        <prism:volume>4</prism:volume>
        <prism:startingPage>1</prism:startingPage>
        <prism:publicationDate>2007-03-20T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.immunityageing.com/content/6/1/13">
        <title>Pathophysiology of vascular dementia</title>
        <description>The concept of Vascular Dementia (VaD) has been recognized for over a century, but its definition and diagnostic criteria remain unclear.Conventional definitions identify the patients too late, miss subjects with cognitive impairment short of dementia, and emphasize consequences rather than causes, the true bases for treatment and prevention. We should throw out current diagnostic categories and describe cognitive impairment clinically and according to commonly agreed instruments that document the demographic data in a standardized manner and undertake a systematic effort to identify the underlying aetiology in each case.Increased effort should be targeted towards the concept of and criteria for Vascular Cognitive Impairment and Post-Stroke Dementia as well as for genetic factors involved, especially as these categories hold promise for early prevention and treatment.</description>
        <link>http://www.immunityageing.com/content/6/1/13</link>
                <dc:creator>Francesco Iemolo</dc:creator>
                <dc:creator>Giovanni Duro</dc:creator>
                <dc:creator>Claudia Rizzo</dc:creator>
                <dc:creator>Laura Castiglia</dc:creator>
                <dc:creator>Vladimir Hachinski</dc:creator>
                <dc:creator>Calogero Caruso</dc:creator>
                <dc:source>Immunity &amp; Ageing 2009, 6:13</dc:source>
        <dc:date>2009-11-06T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1742-4933-6-13</dc:identifier>
        <prism:publicationName>Immunity &amp; Ageing</prism:publicationName>
        <prism:issn>1742-4933</prism:issn>
        <prism:volume>6</prism:volume>
        <prism:startingPage>13</prism:startingPage>
        <prism:publicationDate>2009-11-06T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.immunityageing.com/content/6/1/4">
        <title>Molecular Ageing in Progeroid Syndromes: Hutchinson-Gilford Progeria Syndrome as a model</title>
        <description>Hutchinson-Gilford progeria syndrome (HGPS) is a rare premature aging disorder that belongs to a group of conditions called laminopathies which affect nuclear lamins. Mutations in two genes, LMNA and ZMPSTE24, have been found in patients with HGPS. The p.G608G LMNA mutation is the most commonly reported mutation. The aim of this work was to compile a comprehensive literature review of the clinical features and genetic mutations and mechanisms of this syndrome as a contribution to health care workers. This review shows the necessity of a more detailed clinical identification of Hutchinson-Gilford progeria syndrome and the need for more studies on the pharmacologic and pharmacogenomic approach to this syndrome.</description>
        <link>http://www.immunityageing.com/content/6/1/4</link>
                <dc:creator>Henrique Coutinho</dc:creator>
                <dc:creator>Vivyanne Falcao-Silva</dc:creator>
                <dc:creator>Raphael Nobrega</dc:creator>
                <dc:creator>Gregorio Goncalves</dc:creator>
                <dc:source>Immunity &amp; Ageing 2009, 6:4</dc:source>
        <dc:date>2009-04-20T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1742-4933-6-4</dc:identifier>
        <prism:publicationName>Immunity &amp; Ageing</prism:publicationName>
        <prism:issn>1742-4933</prism:issn>
        <prism:volume>6</prism:volume>
        <prism:startingPage>4</prism:startingPage>
        <prism:publicationDate>2009-04-20T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.immunityageing.com/content/2/1/17">
        <title>Melatonin, immune function and aging</title>
        <description>Aging is associated with a decline in immune function (immunosenescence), a situation known to correlate with increased incidence of cancer, infectious and degenerative diseases. Innate, cellular and humoral immunity all exhibit increased deterioration with age. A decrease in functional competence of individual natural killer (NK) cells is found with advancing age. Macrophages and granulocytes show functional decline in aging as evidenced by their diminished phagocytic activity and impairment of superoxide generation. There is also marked shift in cytokine profile as age advances, e.g., CD3+ and CD4+ cells decline in number whereas CD8+ cells increase in elderly individuals. A decline in organ specific antibodies occurs causing reduced humoral responsiveness. Circulating melatonin decreases with age and in recent years much interest has been focused on its immunomodulatory effect. Melatonin stimulates the production of progenitor cells for granulocytes-macrophages. It also stimulates the production of NK cells and CD4+ cells and inhibits CD8+ cells. The production and release of various cytokines from NK cells and T-helper lymphocytes also are enhanced by melatonin. Melatonin presumably regulates immune function by acting on the immune-opioid network, by affecting G protein-cAMP signal pathway and by regulating intracellular glutathione levels. Melatonin has the potential therapeutic value to enhance immune function in aged individuals and in patients in an immunocompromised state.</description>
        <link>http://www.immunityageing.com/content/2/1/17</link>
                <dc:creator>Venkatramanujam Srinivasan</dc:creator>
                <dc:creator>Georges Maestroni</dc:creator>
                <dc:creator>Daniel Cardinali</dc:creator>
                <dc:creator>Ana Esquifino</dc:creator>
                <dc:creator>S. Pandi-Perumal</dc:creator>
                <dc:creator>Sandra Miller</dc:creator>
                <dc:source>Immunity &amp; Ageing 2005, 2:17</dc:source>
        <dc:date>2005-11-29T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1742-4933-2-17</dc:identifier>
        <prism:publicationName>Immunity &amp; Ageing</prism:publicationName>
        <prism:issn>1742-4933</prism:issn>
        <prism:volume>2</prism:volume>
        <prism:startingPage>17</prism:startingPage>
        <prism:publicationDate>2005-11-29T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.immunityageing.com/content/7/1/3">
        <title>Differential impact of ageing on cellular and humoral immunity to a persistent murine gamma-herpesvirus</title>
        <description>Background:
Oncogenic gamma-herpesviruses establish life-long infections in their hosts and control of these latent infections is dependent on continual immune surveillance. Immune function declines with age, raising the possibility that immune control of gamma-herpesvirus infection becomes compromised with increasing age, allowing viral reactivation and/or increased latent load, both of which are associated with the development of malignancies.
Results:
In this study, we use the experimental mouse gamma-herpesvirus model, gammaHV68, to investigate viral immunity in aged mice. We found no evidence of viral recrudescence or increased latent load in aged latently-infected mice, suggesting that effective immune control of gamma-herpesvirus infection remains intact with ageing. As both cellular and humoral immunity have been implicated in host control of gammaHV68 latency, we independently examined the impact of ageing on gammaHV68-specific CD8 T cell function and antibody responses. Virus-specific CD8 T cell numbers and cytolytic function were not profoundly diminished with age. In contrast, whereas ELISA titers of virus-specific IgG were maintained over time, there was a progressive decline in neutralizing activity. In addition, although aged mice were able to control de novo acute infection with only slightly delayed viral clearance, serum titers of neutralizing antibody were reduced in aged mice as compared to young mice.
Conclusion:
Although there is no obvious loss of immune control of latent virus, these data indicate that ageing has differential impacts on anti-viral cellular and humoral immune protection during persistent gammaHV68 infection. This observation has potential relevance for understanding gamma-herpesvirus immune control during disease-associated or therapeutic immunosuppression.</description>
        <link>http://www.immunityageing.com/content/7/1/3</link>
                <dc:creator>Eric Yager</dc:creator>
                <dc:creator>In-Jeong Kim</dc:creator>
                <dc:creator>Michael Freeman</dc:creator>
                <dc:creator>Kathleen Lanzer</dc:creator>
                <dc:creator>Claire Burkum</dc:creator>
                <dc:creator>Tres Cookenham</dc:creator>
                <dc:creator>David Woodland</dc:creator>
                <dc:creator>Marcia Blackman</dc:creator>
                <dc:source>Immunity &amp; Ageing 2010, 7:3</dc:source>
        <dc:date>2010-02-02T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1742-4933-7-3</dc:identifier>
        <prism:publicationName>Immunity &amp; Ageing</prism:publicationName>
        <prism:issn>1742-4933</prism:issn>
        <prism:volume>7</prism:volume>
        <prism:startingPage>3</prism:startingPage>
        <prism:publicationDate>2010-02-02T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.immunityageing.com/content/6/1/9">
        <title>The immune system and the impact of zinc during aging</title>
        <description>The trace element zinc is essential for the immune system, and zinc deficiency affects multiple aspects of innate and adaptive immunity. There are remarkable parallels in the immunological changes during aging and zinc deficiency, including a reduction in the activity of the thymus and thymic hormones, a shift of the T helper cell balance toward T helper type 2 cells, decreased response to vaccination, and impaired functions of innate immune cells. Many studies confirm a decline of zinc levels with age. Most of these studies do not classify the majority of elderly as zinc deficient, but even marginal zinc deprivation can affect immune function. Consequently, oral zinc supplementation demonstrates the potential to improve immunity and efficiently downregulates chronic inflammatory responses in the elderly. These data indicate that a wide prevalence of marginal zinc deficiency in elderly people may contribute to immunosenescence.</description>
        <link>http://www.immunityageing.com/content/6/1/9</link>
                <dc:creator>Hajo Haase</dc:creator>
                <dc:creator>Lothar Rink</dc:creator>
                <dc:source>Immunity &amp; Ageing 2009, 6:9</dc:source>
        <dc:date>2009-06-12T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1742-4933-6-9</dc:identifier>
        <prism:publicationName>Immunity &amp; Ageing</prism:publicationName>
        <prism:issn>1742-4933</prism:issn>
        <prism:volume>6</prism:volume>
        <prism:startingPage>9</prism:startingPage>
        <prism:publicationDate>2009-06-12T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.immunityageing.com/content/7/1/2">
        <title>Age-related changes in plasma levels of BDNF in Down syndrome patients</title>
        <description>Background:
The prevalence of coronary artery diseases is low among Down Syndrome (DS) patients and they rarely die of atherosclerotic complications. Histopathological investigations showed no increase in atherosclerosis, or even a total lack of atherosclerotic changes, in DSAimThe aim of our study is to investigate the relationship between age and brain-derived neurotrophic factor (BDNF) levels in Down Syndrome (DS).Subjects and methodsThree groups of DS patients were studied: the first consisted of 23 children (age 2-14 years); the second of 14 adults (age 20-50 years), the third group of 13 elderly persons (&gt;60 years) and a controls group of 20 healthy patients (age 15-60 years).The analytes of interest were quantified using a biochip array analyzer (Evidence&#174;, Randox Ltd., Crumlin, UK).
Results:
Plasma BDNF was higher in DS patients than in controls and there was a significant age-related increase. Serum levels of IL-6 and MCP-1 were also higher in DS children and adults, but not in older patients, than in healthy control. High levels of circulating BDNF may protect DS patients from the clinical complications of atherosclerosis. However, the striking drop in peripheral BDNF levels with age might predispose these patients to clinical manifestations of dementia in later life.</description>
        <link>http://www.immunityageing.com/content/7/1/2</link>
                <dc:creator>Giada Dogliotti</dc:creator>
                <dc:creator>Emanuela Galliera</dc:creator>
                <dc:creator>Federico Licastro</dc:creator>
                <dc:creator>Massimiliano Corsi</dc:creator>
                <dc:source>Immunity &amp; Ageing 2010, 7:2</dc:source>
        <dc:date>2010-01-25T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1742-4933-7-2</dc:identifier>
        <prism:publicationName>Immunity &amp; Ageing</prism:publicationName>
        <prism:issn>1742-4933</prism:issn>
        <prism:volume>7</prism:volume>
        <prism:startingPage>2</prism:startingPage>
        <prism:publicationDate>2010-01-25T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
        <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks" />
    </cc:License>
</rdf:RDF>
